PARSIPPANY, N.J., Sept. 10 NJ-FerringPharm-elect
PARSIPPANY, N.J., Sept. 10 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a
specialty pharmaceutical company, announces the appointment of Paul Korner,
M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be
responsible for Medical Affairs for Ferring's Infertility, Orthopaedics,
Urology, and Gastroenterology therapeutic areas as well as Product Safety.
"As a result of our continued and projected growth, we have expanded and
realigned our management staff to best meet our business needs," said Wayne
Anderson, President and CEO. "Dr. Korner is exceptionally well qualified to
fill this new role, as we continue our quest to achieve rapid new drug
approvals by identifying, improving and commercializing late-stage or marketed
products in our clinical specialty areas."
Dr. Korner joins Ferring with a broad range of experience in medical
affairs, clinical development, management and business development. Prior to
joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women's
Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the
U.S. Women's Healthcare business unit, and managed medical experts supporting
Phase II and III development projects. He has also served as Executive
Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc.,
and Senior Director of Clinical Research and Development, Women's Health and
Bone Repair for Wyeth Research.
Dr. Korner is a board certified obstetrician and gynecologist. He
received his M.D. from Loyola University, Stritch School of Medicine near
Chicago. He also holds an M.B.A. from the Michael J. Coles College of
Business at Kennesaw State University in Georgia.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately
owned, international pharmaceutical company. Ferring's line of products
includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the
knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R)
(menotropins for injection, USP); REPRONEX(R) (menotropins for injection,
USP); Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R)
(progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM),
the first needle-free reconstitution device, for use with its fertility
treatments.
Other products include: ACTHREL(R) (corticorelin ovine triflutate for
injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN
ACETATE in injectable and rhinal tube forms for the treatment of diabetes
insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of
discomfort of the lower urinary tract.
The Ferring Group specializes in the research, development and
commercialization of compounds in general and pediatric endocrinology,
urology, gastroenterology, obstetrics/gynecology, orthopaedics and
infertility. For more information, call 888-337-7464 or visit
www.FerringUSA.com.
SOURCE Ferring Pharmaceuticals Inc.
